Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTAFR | P25105 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6569154 | 0.99 | TBXAS1 (0.62) | TBXAS1TDP1L3MBTL1HRH1MAPT | |
| SCHEMBL7448948 | 0.94 | TBXAS1 (0.56) | TBXAS1TDP1L3MBTL1HRH1PTAFR | |
| Bicarbonate SCHEMBL9520631 | 0.85 | TBXAS1 (0.64) | TBXAS1TDP1L3MBTL1HRH1PTAFR | |
| SCHEMBL6570937 | 0.83 | MAPT (0.59) | MAPT | |
| SCHEMBL7760926 | 0.82 | TDP1 (0.64) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL6571377 | 0.81 | LMNA (0.57) | MAPT | |
| SCHEMBL12197971 | 0.79 | TDP1 (0.62) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL7448526 | 0.78 | TBXAS1 (0.63) | TBXAS1TDP1L3MBTL1HRH1MAPT | |
| SCHEMBL7443753 | 0.78 | TBXAS1 (1.00) | TBXAS1TDP1L3MBTL1HRH1MAPT | |
| SCHEMBL1009589 | 0.78 | TBXAS1 (1.00) | TBXAS1TDP1L3MBTL1HRH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001079177-A1 | CYCLIC DIAZA COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |